Physician profile
Harry He
NPI 1215427588
$6,351.30
in general payments reported to CMS, 2019-2025
22 companies · $3,344 in 2025
The $3,344 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,036 · 2024: $1,970 · 2025: $3,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,351.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $846.06 | 2023-2025 | |
| Madrigal Pharmaceuticals | $820.46 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $668.05 | 2023-2025 | Resolution 360 Ultra Clip, Resolution Clip, Axios |
| Celltrion USA INC. | $664.39 | 2025 | Zymfentra, Vegzelma |
| Phathom Pharmaceuticals, INC. | $600.31 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $332.87 | 2024-2025 | Epclusa, Livdelzi |
| Ardelyx, INC. | $274.98 | 2023-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $265.92 | 2023 | Terlivaz |
| Janssen Biotech, INC. | $264.79 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $222.24 | 2023-2025 | Entyvio |
| Genzyme Corporation | $211.38 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $148.27 | 2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.29 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $125.00 | 2024 | Xarelto |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $125.00 | 2024 | |
| Qol Medical, LLC | $122.19 | 2024 | Sucraid |
| Novo Nordisk INC | $122.19 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $120.13 | 2024 | Dupixent |
| Aimmune Therapeutics, INC. | $119.59 | 2025 | Zenpep |
| Amgen INC. | $21.46 | 2025 | |
| Exact Sciences Corporation | $18.73 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.